We developed a novel algorithm to define the need for high-dose prophylactic i.v. Igs (IVIG) in periods of high risk for CMV to patients after allo-SCT. IVIG were administered only if at least one of the following, monthlyassessed, criteria was fulfilled: (1) IgG concentration o4 g/l, (2) NK (natural killer) cell count o100/ll, (3) CD4 þ cell count o100/ll, (4) acute or chronic GVHD. The primary endpoint was to determine the cumulative incidence of CMV infection in patients who received prophylactic IVIG according to the algorithm (intervention group) and compare it with that of a sequentially assessed control group, to which prophylactic IVIG were not administered. The study included 79 patients (44 in the intervention and 35 in the control group). The estimated cumulative incidence of CMV infection in the intervention and control group did not differ significantly (44 and 36%; P ¼ 0.31). Additionally, prophylactic IVIG did not reduce the frequency of CMV infection episodes. CMV disease was rare in both cohorts (5 and 9%; P ¼ 0.65). We conclude that prophylactic IVIG should not be administered after allo-SCT, even if administered selectively in a high dose to patients with delayed immune reconstitution or GVHD.
Introduction
Viral infections, in particular by CMV, are still a major cause of morbidity and mortality after allo-SCT. 1 Although the incidence of CMV infection and disease has been remarkably reduced in the early phase after allo-SCT (pday þ 90) by the prophylactic and preemptive use of antiviral agents and the almost exclusive use of screened CMV negative or leukocyte-depleted blood products, earlier publications suggest an increase in fatal CMV diseases in the late phase (4day þ 90). [1] [2] [3] [4] The major risk factor for CMV infection in the early and late phase after allo-SCT is the recipients' CMV seropositivity, whereas patients with a CMV seronegative donor might have the highest risk. 3 In addition, a higher treatment-related mortality (TRM) and a lower OS have been reported for CMV seropositive patients with a CMV seronegative donor compared with those who have a CMV seropositive donor. 5 However, the impact of the donors' CMV serostatus still remains controversial. 6 Further risk factors for CMV infection in the early phase include the use of T-cell-depleted grafts, alemtuzumab or antithymocyte globulin as conditioning therapy or prophylaxis for acute GVHD. 7, 8 Risk factors for CMV infection or disease in the late phase are predominately acute or chronic GVHD and CMV infection in the early phase. [1] [2] [3] Additionally, delayed immunological recovery of CMV-specific T cells, CD4 þ cells or NK (natural killer) cells has been found to be associated with a high risk for CMV infection early or late after allo-SCT. 1, 9, 10 Many strategies for preventing CMV infection and disease after allo-SCT have been undertaken in recent years: antiviral agents, including ganciclovir and foscarnet, are in standard use for preventing and treating CMV infection and disease. However, these agents cause significant side effects and a rising resistance has been reported. 11 The adoptive transfer of CMV-specific T and NK cells is currently being assessed, but remains very costly, time-consuming and not widely established. 12 The prophylactic use of i.v. Igs (IVIG) seems to be an attractive option, as patients undergoing allo-SCT frequently present a long-lasting B-cell deficiency. 13 During the last two decades, a number of trials have been carried out to investigate the efficacy of prophylactic IVIG in preventing CMV after allo-SCT. [14] [15] [16] However, the results still remain controversial: Some trials as well as in vitro data suggest that infectious complications, in particularly CMV pneumonitis and GVHD, might be reduced by the prophylactic use of IVIG. [15] [16] [17] [18] By contrast, a recently published placebo-controlled trial found no benefit from prophylactic IVIG with respect to CMV, GVHD, TRM and OS, whereas patients with hypogammaglobulinemia (IgG o4 g/l) were excluded because of the recommendations of the 'Center for Disease Control and Prevention'. 14, 19 Despite the potential benefit of prophylactic IVIG in patients after allo-SCT, recent reports indicate that they might be related to important side effects, including an increased risk of sinusoidal obstruction syndrome or delay in immune recovery. 14, 20, 21 Prophylactic use of high-dose IVIG focusing on patients with delayed immune reconstitution including hypogammaglobulinemia, has not yet been evaluated after allo-SCT. We developed a novel algorithm, based on immunological recovery and GVHD, to define the need for high-dose IVIG only in periods of high risk for CMV to patients after allo-SCT.
Patients and methods

Patients and study design
Patients who underwent allo-SCT between June 2005 and October 2006 received prophylactic IVIG according to the algorithm (intervention group), whereas to those who were allografted between November 2006 and January 2008 prophylactic IVIG were not administered (control group). The algorithm was started on day þ 30 and continued up to the maximum of 1 year after allo-SCT (Figure 1 ). Immunoparameters and GVHD were assessed monthly and IVIG (FlebogammaÀ5%, Grifols, Langen; Germany) were applied at a dose of 500 mg/kg body weight (BW) twice monthly only if at least one of the following criteria was fulfilled: (1) serum IgG concentration o4 g/l, (2) NK cell count o100/ml, (3) CD4 þ cell count o100/ml, (4) acute (grade II-IV) or chronic (extensive) GVHD. Administration of IVIG according to the algorithm was terminated before the maximum of 1 year after allo-SCT in the case of intolerability, 'fulminant' relapse/progression of the underlying malignancy (defined by the requirement of subsequent chemotherapy, second allo-SCT or life expectancy o3 months), death or patient's refusal to continue the protocol. Administration of IVIG was continued in patients who developed CMV infection or disease according to the algorithm until one of these criteria has been reached.
The primary endpoint was to determine the cumulative incidence of CMV infection in patients of the intervention group in comparison with those of the control group. Secondary endpoints encompassed cumulative incidence of CMV disease, mean number of CMV infection episodes, TRM, OS, GVHD and toxicity.
Immunological monitoring and assessment of GVHD
were measured by using a FACSscan and a commercially available Cell Quest Software (Becton Dickinson, Heidelberg, Germany). The serum IgG concentration was determined by a standard photometer (Cobas system, Roche Diagnostics GmbH, Mannheim, Germany). Acute GVHD was graded according to the revised Glucksberg scale. 22 Chronic GVHD was assessed in patients with a survival or follow-up of at least 100 days and scored according to the revised Seattle criteria. 23 Toxicity was evaluated using the common toxicity criteria (CTC, version 2).
Assessment and management of CMV
The CMV serostatus of patients and donors was determined prior to allo-SCT by an ELISA. After transplantation, patients were monitored for CMV infection (CMV antigenemia or DNAemia) at least weekly up to day þ 100 Defined by the requirement of subsequent chemotherapy, second allo-SCT or life expectancy o3 months (donor lymphocytic infusion and modulations of immunosuppression did not lead to 'end of the investigation'). CTC, common toxicity criteria; NK, natural killer.
and every 2-4 weeks thereafter. CMV infection was defined as a positive pp65 Ag assay (X2 cells of 200 000 leucocytes) or positive plasma CMV DNA detected by an in-house real-time PCR using TaqMan primers (X750 DNA copies/ ml) without any evidence of CMV end-organ disease. 24 CMV disease (proven) was defined as published elsewhere. 25 Probable CMV disease was diagnosed if typical symptoms of CMV end-organ disease were present (for example, diarrhea), together with CMV antigenemia or detection of CMV DNA in the peripheral blood and response to antiviral treatment (but organ biopsy was not carried out or showed ambiguous results). One CMV infection episode was considered to extend from the first day of CMV infection until the first of two subsequent samples became CMV negative. Treatment of either CMV infection or disease consisted of i.v. ganciclovir (5 mg/kg BW twice daily), which was switched to foscarnet (120-180 mg/d in two or three divided doses) in the case of lack of efficacy or intolerability. Administration of ganciclovir or foscarnet was discontinued if two subsequent peripheral blood samples became CMV negative.
Concomitant treatment and prophylaxis
All patients were housed in laminar airflow rooms until discharge and received leukocyte-depleted and irradiated blood products. Patients received intestinal decontamination with levofloxacin and antifungal prophylaxis with fluconazole from the day of allo-SCT until neutrophil reconstitution. Prophylaxis for Pneumocystis jirovecii pneumonia was carried out by trimethoprim/sulfamethoxazole from day À6 to day À2 and then again from neutrophil reconstitution until the peripheral CD4 þ lymphocyte count exceeded 400/ml. Patients additionally received acyclovir from the day of allo-SCT until the peripheral count of CD4 þ lymphocytes exceeded 200/ml. CMV seropositive patients transplanted from a CMV seronegative donor further received CMV prophylaxis with i.v. ganciclovir (5 mg/kg BW twice daily) for three consecutive days prior to allo-SCT.
Definitions and statistical considerations
Results were analyzed on an intent-to-treat basis, whereas patients who died before day þ 30 were included in both cohorts. The reference date used was 15 February 2008. The cumulative incidence of CMV infection was calculated by the number of patients with at least one CMV infection episode compared with those in whom CMV was not detected at any time during the study period. Treatmentrelated mortality was defined as any death after allo-SCT not caused by relapse or disease progression. Calculation of 'time to CMV infection' (estimated cumulative incidence of CMV infection) was based on the time of allo-SCT until the first day of CMV infection or achievement of one of the endpoints specified in Figure 1 . OS and 'time to TRM' were considered as the time from allo-SCT until the censored event, day þ 365 after allo-SCT or the last followup before day þ 365. Estimates were calculated by the Kaplan-Meier method and compared between the intervention and control groups using the log-rank test (software SPSS 14.0 for Windows XP). P-values below 0.05 were considered significant (two-sided). Categorical data were compared by using Fisher's exact test, while the Wilcoxon-two sample test (Wilcoxon Mann-Whitney U test) was used to analyze the number of CMV infection episodes.
Results
Patients
Patient characteristics are shown in Table 1 . The study comprised 79 patients in total, 44 patients being allocated to the intervention group and 35 to the control group. We did not observe any significant difference between the patient characteristics of the two cohorts. In both groups, the most frequent underlying disease was AML and the majority of patients received a fludarabine-based reducedintensity conditioning regimen prior to allo-SCT. In the intervention group, 15 patients (34%) achieved 1-year survival, 9 patients (20%) suffered from fulminant relapse/ disease progression, 13 patients (30%) died before day þ 365 and 7 patients (16%) were followed up for less than 365 days after allo-SCT. Two patients (6%) of the control group achieved 1-year survival, 1 patient (2.5%) suffered from relapse, 7 patients (20%) died before day þ 365 and 25 patients (71.5%) were followed up for less than 365 days after allo-SCT.
Thirty-three patients (75%) of the 44 patients who were attached to the intervention group received prophylactic IVIG at least once. Including all patients of the intervention group, the total number of terms of immunomonitoring was 277 (median 6, range 1-12). Characteristics of fulfilled events according to the algorithm are summarized in Table 2 . Although a total of 258 administrations of IVIG were scheduled by the algorithm (criteria for IVIG administration fulfilled at 129 terms of immunomonitoring, IVIG administration twice monthly), only 114 administrations were given (44%) (Figure 2 ). Reasons for not administering IVIG according to the algorithm included patients' unavailability (for example, treatment at a health resort), administrative reasons (impossibility to coordinate the timing of immunomonitoring and IVIG administration), patient's refusal or toxicity (please see below). Five patients of the control group received IVIG, although this was not planned by the protocol (three patients 500 mg/kg BW, one administration; two patients 500 mg/kg BW, two administrations). Reasons for administering IVIG to patients attached to the control group included treatment of idiopathic thrombocytopenic purpura (ITP; 1 patient) and decision in respect of the accountability of the responsible physician (4 patients).
CMV infection and disease The cumulative incidence of CMV infection was 43% (19 of 44 patients) in the intervention group and 31% (11 of 35 patients) in the control group (P ¼ 0.35). As the median follow-up was shorter in the control group than in the intervention group (Table 1) , we also analyzed 'time to CMV infection'. The estimated cumulative incidence of CMV infection was 44% in the intervention group and 36% in the control group 1 year after allo SCT (P ¼ 0.31, Figure 3a) . With a number of 44 (35) subjects per group and a power of 80%, a hazard ratio of 3.05 (3.45) could have been detected on a two-sided significance level of 0.05.
In our study, the hazard ratio with respect to CMV infection was 1.5.
As protocol violations occurred in both the intervention and control group, we further compared 'time to CMV In this sub-analysis, the estimated cumulative incidence of CMV infection 1 year after SCT also did not differ significantly between both cohorts (intervention group 58%, control group 43%; P ¼ 0.15). In addition we analyzed the percentage of patients who finally received IVIG and those who developed CMV infection at a certain time point after allo-SCT (Figure 2 ). This analysis shows that the majority of IVIG administrations were carried out between day þ 30 and day þ 90, and thus in the same period in which the majority of CMV infections was observed. Finally, the estimated cumulative incidence of CMV infection in the intervention and the control group was comparable, when considering only CMV seropositive patients (58%, n ¼ 32 and 55%, n ¼ 25 1 year after allo-SCT; P ¼ 0.43) or patients who did not develop CMV infection before initiation of the algorithm at day þ 30 (32%, n ¼ 36 and 31%, n ¼ 33; P ¼ 0.89).
On including all patients, the mean number of CMV infection episodes was comparable between the intervention and control group (1.7 and 1.5, respectively; range for both 0-3; P ¼ 0.55). Two patients of the intervention group and three patients of the control group showed proven or probable CMV disease (5 and 9%, respectively; P ¼ 0.65); in the intervention group one patient showed proven CMV colitis and one patient probable CMV hepatitis. In the control group, one patient showed proven CMV colitis, one patient probable CMV pneumonitis/CMV colitis and one patient probable CMV colitis. Proven or probable CMV disease resolved after initiation of ganciclovir or foscarnet therapy in all patients, and did not contribute to death in any of them.
TRM, OS, GVHD and toxicity
The TRM assessed by the Kaplan-Meier method was 27 and 24% 1 year after allo-SCT in the intervention and control groups, respectively (P ¼ 0.44; Figure 3b ). In the intervention group the OS was 52% one year after allo-SCT, whereas in the control group it was 70% (P ¼ 0.34; Figure 3c ). The overall mortality at the last follow-up was 39% (17 of 44 patients) in the intervention group; six of these patients died because of relapse/progression of the underlying disease and 11 because of treatment-related complications (sepsis including invasive fungal infection in nine, GVHD and heart failure in one patient each). The overall mortality at the last follow-up was 20% (7 of 35 patients) in the control group; two of these patients died due to relapse and five because of treatmentrelated complications (sepsis in four, heart failure in one patient).
Grade 0/I, II and III-IV acute GVHD occurred in the intervention group in 41% (18 of 44 patients), 23% (10 of 44 patients) and 36% (16 of 44 patients) of the patients, respectively. In the control group, grade III/IV acute GVHD was observed in 17.5% (6 of 34 evaluable patients; P ¼ 0.08), whereas grade 0/I and grade II acute GVHD Table 2 Fulfilled events according to the algorithm specified in Figure 1 The number of patients in whom a certain criterion was fulfilled at the respective day after allo-SCT in comparison to the number of evaluable patients at the same time point (%) is shown.
Prophylactic IVIG after SCT M Schmidt-Hieber et al occurred in 65% (22 of 34 patients) and 17.5% (6 of 34 patients). Chronic GVHD (including limited and extensive disease) was observed in 60% (18 of 30 evaluable patients) in the intervention group and 43% (10 of 23 evaluable patients) in the control group (P ¼ 0.40). IVIG-related toxicities (rash, fever, shivering, CTC grade 1-2) were observed in four patients of the intervention group (9%) and led to premature termination of the algorithm due to patient's decision. One patient of the intervention group (2%, P ¼ 1.00) developed possible sinusoidal obstruction syndrome (CTC grade 0-1). However, it occurred before IVIG administration and rapidly resolved after initiation of defibrotide therapy.
Discussion
A survey by the European Group for Blood and Marrow Transplantation (EBMT) showed that 55% of 45 European allo-SCT centers continue to routinely give prophylactic IVIG to patients after allo-SCT. 26 Presumably, the fact that IVIG are approved for prevention of GVHD and infections during the first 90 days after allo-SCT contributes to this policy. 16 However, the data regarding the benefit of prophylactic administration of IVIG after allo-SCT remain controversial and contradictory. An earlier meta-analysis encompassing 1282 patients after BMT showed that prophylactic IVIG significantly reduces fatal CMV disease, showed at least one CMV infection episode between two adjacent time points (triangles).
Prophylactic IVIG after SCT M Schmidt-Hieber et al CMV pneumonia, non-CMV interstitial pneumonia and total mortality. 27 In contrast, others did not find any significant reduction in CMV or GVHD. 14, 28 It is noted that patients with reduced serum IgG (o4 g/l) were excluded from the controlled trial recently published by Cordonnier et al.
14 on the basis of the recommendation of the 'Centers for Disease Control and Prevention' to substitute IVIG in the case of hypogammaglobulinemic stem cell or BM recipients. 19 We developed a novel algorithm on the basis of immunological recovery and GVHD to investigate the efficacy of prophylactic IVIG applications in stem cell recipients with hypogammaglobulinemia or delayed immune reconstitution, that is, patients with a high risk for CMV. As it cannot be excluded that lack of efficacy of prophylactic IVIG administration in earlier studies may be due to insufficient IVIG dosages, high IVIG dosages (500 mg/kg BW) were used in this novel approach. 29 The estimated cumulative incidence of CMV infection 1 year after allo-SCT was 44% in patients of the intervention group who received prophylactic IVIG according to the algorithm, and thus did not differ significantly from those of a sequentially assessed control group who did not receive prophylactic IVIG (36%). Remarkably, the cumulative incidence of CMV disease at the last follow-up was low in both cohorts (5 and 9%). In contrast to our results, Sullivan et al. 16 found interstitial pneumonia in 22% of 308 CMV seropositive BM recipients who did not receive IVIG, but only in 13% of those who received prophylactic IVIG. However, this trial was conducted more than 15 years ago, before the routine use of screened CMV negative blood products and prophylactic and preemptive strategies by antiviral agents. It might therefore be assumed that these strategies significantly reduce the risk of CMV disease, as shown in our analysis for both the intervention and the control group, but that prophylactic IVIG does not contribute to a further reduction in the incidence of CMV disease. Despite the low incidence of CMV disease shown in our investigation, the estimated cumulative incidence of CMV infection 1 year after allo-SCT was remarkable, with 44% of the patients of the intervention group who received prophylactic IVIG according to the algorithm. These observations suggest that prophylactic IVIG does not reduce the frequency of CMV infection, even if administered selectively at a high dose to patients with delayed immune reconstitution or GVHD.
It was recently shown that hypogammaglobulinemia (serum IgG o4 g/l) during the first year after allo-SCT is associated with an increased TRM and reduced OS. 30 From their data, the authors concluded that the benefit of IVIG should be examined in that specific patient group with hypogammaglobulinemia. In our analysis, IVIG was not administered exclusively to patients with hypogammaglobulinemia, but also to patients with delayed reconstitution of CD4 þ cells, NK cells or presence of GVHD. We did not find any substantive benefit of prophylactic IVIG in terms of TRM, OS or occurrence of GVHD, although the limited number of patients precludes a more detailed analysis.
Our study has some limitations: there was no blinding, and the intervention and control groups were assessed sequentially. Furthermore, protocol violations occurred in both the intervention and the control group, that is, some of the patients in the intervention group did not receive IVIG as scheduled by the algorithm and few patients of the control group received IVIG. Thus, we carried out a subanalysis evaluating patients of the intervention group who finally received at least three administrations of IVIG (median 4, range [3] [4] [5] [6] [7] [8] [9] [10] , and compared the results with those of patients of the control group who did not receive any IVIG. In this sub-analysis, the estimated cumulative incidence of CMV infection was also not decreased in the intervention group in comparison with the control group (58 and 43% 1 year after SCT). We also determined the percentage of patients who finally received IVIG at a certain day after allo-SCT. The fact that the majority of IVIG administrations were done between day þ 30 and day þ 90, and thus in the same period in which the majority of CMV infections occurred, supports the hypothesis that CMV infection may develop in spite of IVIG application. In addition, we focused on CMV seropositive patients, who are characterized by a particularly high risk of developing CMV infection and we also found a comparable cumulative incidence of CMV infection in both cohorts (58 and 55%).
Despite these limitations, we showed in a prospective analysis using a novel approach that prophylactic IVIG does not reduce the cumulative incidence of CMV infection or disease, even if administered selectively at a high dose to patients with delayed immune reconstitution or GVHD. It is noted that, particularly those patients with high CMV risk have been partially excluded in some earlier trials as it was assumed that they may benefit from prophylactic IVIG. Our data do not support the use of prophylactic IVIG after allo-SCT, which is still carried out routinely in many allogeneic transplant centers throughout Europe. This issue has become particularly important in recent years, as pharmaco-economic aspects are becoming increasingly relevant and IVIG in high doses are extremely expensive.
